Opinion|Videos|August 21, 2024
Strategies for Treatment Optimization and Adverse Event Reduction in Myelofibrosis
Dr Mahmoudjafari shares clinical strategies for optimizing patient outcomes and reducing the rate of adverse events and treatment discontinuations.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- At what point is it recommended for a patient's treatment regimen to change?
- What are some considerations for continuing or altering treatment regimens in myelofibrosis?
Advertisement
Related to this article
A meta-analysis of 13 trials and 969 patients saw some short-term reductions in cancer-related pain and anxiety, especially during procedures, when using virtual reality.
Chad Hatfield, Pharm.D., M.H.A., BCPS, vice president and chief pharmacy officer of UC Davis Health, says pharmacists are embedded in “nearly all specialties," with more than 150 holding board certification.
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
8-year data show adjuvant Tagrisso boosts survival after surgery for EGFR-mutated NSCLC, reshaping early Lung Cancer care and adherence.
Sova, a clinical advisor for Employers Health, expects more employers to exclude GLP-1s for obesity but urges a look at coverage for specific cardiometabolic conditions.
Employers Health’s Alexis Sova says employers excluding GLP-1s now lean on weight management programs and direct-to-employer deals, not a hard cutoff.
Approximately two-thirds of Employers Health clients now exclude GLP-1s for obesity, up from a roughly even split at launch as cost drives coverage decisions.
Chad Hatfield, Pharm.D., MHA, BCPS, of UC Davis Health, discusses the system's pharmacy shared service center, embedded pharmacists and 340B rebate readiness.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Alexis Sova, Pharm.D., MBA, on where GLP-1 coverage goes next | PBMI 2026
2
Systemic inflammation present even in mild hidradenitis suppurativa
3
Alexis Sova, Pharm.D., MBA, on GLP-1 access when coverage ends | PBMI 2026
4
Large study finds GLP-1 drugs may lower fracture risk in Type 2 diabetes
5